Vir unveils series of deals, additional funding

Vir Biotechnology Inc. (San Francisco, Calif.) revealed a crop of new deals and said it has raised more than $500 million to date. CEO George Scangos told BioCentury the company's current round of funding remains open, and said Vir is discussing additional acquisitions and collaborations.

Vir is taking a multiplatform approach to treat and protect against chronic infectious diseases, respiratory diseases and hospital-acquired infections. The company is accumulating externally developed compounds and platforms, and is also developing undisclosed internal research programs...